- Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
-
Ren TY, Eslam M, Fan JG
- KMID: 2560122
- Clin Mol Hepatol.
- 2024 Oct;30(4):1039-1041.
- doi: 10.3350/cmh.2024.0801
-
- CITED
-
- Close
- SHARE
-
- Close
- Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis”
-
Ren TY, Eslam M, Fan JG
- KMID: 2560061
- Clin Mol Hepatol.
- 2024 Oct;30(4):649-652.
- doi: 10.3350/cmh.2024.0558
-
- CITED
-
- Close
- SHARE
-
- Close
- MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
-
Kawaguchi T, Tsutsumi T, Nakano D, Eslam M, George J, Torimura T
- KMID: 2528243
- Clin Mol Hepatol.
- 2022 Apr;28(2):150-163.
- doi: 10.3350/cmh.2021.0310
Fatty liver is now a major cause of liver disease in the Asia-Pacific region. Liver diseases in this region have distinctive characteristics. First, fatty liver is frequently observed in lean/normal-weight... -
- CITED
-
- Close
- SHARE
-
- Close
- Acute hepatitis A, B and C but not D is still prevalent in Mongolia: a time trend analysis
-
Baatarkhuu O, Lee HW, George J, Munkh-Orshikh D, Enkhtuvshin B, Ariunaa S, Eslam M, Ahn SH, Han KH, Kim DY
- KMID: 2413118
- Clin Mol Hepatol.
- 2017 Jun;23(2):147-153.
- doi: 10.3350/cmh.2016.0055
BACKGROUND/AIMS: Mongolia has one of the highest hepatitis A, C, B and D infection incidences worldwide. We sought to investigate changes in the proportion of acute viral hepatitis types in... -
- CITED
-
- Close
- SHARE
-
- Close
